AstraZeneca ups the ante in EGFR race with Clovis
This article was originally published in Scrip
Executive Summary
AstraZeneca and Clovis Oncology are neck-and-neck in the race to bring next-generation epidermal growth factor receptor (EGFR) inhibitors to the market for lung cancer, but AstraZeneca may one-up Clovis with a new drug application (NDA) submission to the US FDA in the first quarter of 2015.